Wave Life Sciences stock trades at EUR 3.18 before Research Day
Published on 11/03/2026 at 14:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWave Life Sciences ahead of Research Day
- Wave Life Sciences is scheduled to present new platform data at a virtual Research Day on Wednesday, November 4.
- The company develops RNA medicines using editing, splicing, RNA interference and antisense silencing approaches.
- Its lead programs target obesity, alpha-1 antitrypsin deficiency and PNPLA3 I148M liver disease.
Wave Life Sciences stock traded at 3.18 euros on Lang & Schwarz at 14:12 CET on Tuesday, November 3, 2026. The quote is a standalone market snapshot ahead of the company's scheduled research update.
Wave Life Sciences' investor-relations website lists the 2026 Virtual Research Day for Wednesday, November 4, at 9:30 a.m. EST. The company says the event will focus on its RNA medicines platform and provides a webcast link through its corporate site.
Platform data remains the next catalyst
Wave describes its PRISM platform as combining multiple RNA medicine modalities with chemistry innovation and insights from human genetics. Its toolkit includes editing, splicing, RNA interference and antisense silencing.
The lead pipeline includes WVE-007 for obesity, WVE-006 for alpha-1 antitrypsin deficiency and WVE-008 for PNPLA3 I148M liver disease. Investors will be watching the Research Day for updates that could clarify development priorities and the data supporting these programs.
Investors can follow the real-time quote of Wave Life Sciences stock for further trading updates.
Wave Life Sciences stock snapshot
- Company: Wave Life Sciences Ltd.
- ISIN: US94352A1043
- Ticker: WVE
- Trading venue: Lang & Schwarz
- Quote: 3.18 euros on Tuesday, November 3, 2026, at 14:12 CET
US stocks remain part of the broader S&P 500 market environment; see Current market reports.
More news and analyses on Wave Life Sciences stock are available in the topic section.
